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Abstract
Background: Osteosarcoma is the most common primary malignancy of bone with poorly characterized molecular
pathways important in its pathogenesis. Increasing evidence indicates that elevated lipid biosynthesis is a characteristic
feature of cancer. We sought to investigate the role of lysophosphatidic acid acyltransferase b (LPAATb, aka, AGPAT2) in
regulating the proliferation and growth of human osteosarcoma cells. LPAATb can generate phosphatidic acid, which plays
a key role in lipid biosynthesis as well as in cell proliferation and survival. Although elevated expression of LPAATb has been
reported in several types of human tumors, the role of LPAATb in osteosarcoma progression has yet to be elucidated.
Methodology/Principal Findings: Endogenous expression of LPAATb in osteosarcoma cell lines is analyzed by using semi-
quantitative PCR and immunohistochemical staining. Adenovirus-mediated overexpression of LPAATb and silencing
LPAATb expression is employed to determine the effect of LPAATb on osteosarcoma cell proliferation and migration in vitro
and osteosarcoma tumor growth in vivo. We have found that expression of LPAATb is readily detected in 8 of the 10
analyzed human osteosarcoma lines. Exogenous expression of LPAATb promotes osteosarcoma cell proliferation and
migration, while silencing LPAATb expression inhibits these cellular characteristics. We further demonstrate that exogenous
expression of LPAATb effectively promotes tumor growth, while knockdown of LPAATb expression inhibits tumor growth in
an orthotopic xenograft model of human osteosarcoma.
Conclusions/Significance: Our results strongly suggest that LPAATb expression may be associated with the aggressive
phenotypes of human osteosarcoma and that LPAATb may play an important role in regulating osteosarcoma cell
proliferation and tumor growth. Thus, targeting LPAATb may be exploited as a novel therapeutic strategy for the clinical
management of osteosarcoma. This is especially attractive given the availability of selective pharmacological inhibitors.
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Introduction
Osteosarcoma (OS) is the most common primary malignancy of
bone and accounts for ,5% of childhood tumors in the United
States with incidence peaking during the second decade of life
[1–5]. The molecular pathogenesis underlying OS development
remains to be thoroughly elucidated [4,6]. At presentation,
approximately 80% of patients are afflicted by some degrees of
metastasis mandating management through chemotherapy and
surgical resection [7–10]. Pulmonary metastasis remains the main
cause of death in patients with OS [4,11]. Many variants of
OS are relatively resistant to current chemotherapy regimens
[5,12,13]. We and others have reported that numerous genetic
alterations may be found in OS tumors [4–6,14–16]. However, it
remains challenging to identify common genetic alterations that
lead to OS development given the diversity and complexity in its
pathogenesis [4,17–21].
Lysophosphatidic acid acyltransferase (LPAAT, aka, 1-acylgly-
cerol-3-phosphate O-acyltransferase 2, Agpat2) comprises a family
of trans-membrane proteins consisting of at least six isoforms. The
biological role of LPAAT is to convert lysophosphotidic acid (LPA)
into phosphatidic acid (PA) [22], while only the a and b isoforms
have significant acyltransferase activity [23]. LPAATb expression
is specific to heart, liver, adipose and pancreas [24–26]. Inherited
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autosomal recessive condition characterized by impaired triglyc-
eride synthesis, low body fat percentage and insulin resistance
[27].
PA is an important metabolite involved in phospholipid
biosynthesis and membrane remodeling [28]. PA is considered
an important secondary messenger capable of modulating
pathways responsible for cell survival and proliferation, such as
the mTOR and Raf-1 signaling cascade [29–32]. Increasing
evidence indicates that enhanced lipid biosynthesis is a character-
istic feature of cancer and deregulated lipogenesis plays an
important role in tumor cell survival [33–36]. In fact, the
oncogenic nature of lipogenesis closely depends on the activity
and/or expression of key cancer-related oncogenes, such as HER2
[34]. Targeted gene deletion of LPAATb in mice results in a
complete absence of both white and brown adipose tissue [37],
providing a biochemical link between the triglyceride synthesis
pathway and adipogenesis in the liver and adipose tissue. Thus, it
is conceivable that LPAATb may play an important role in
regulating cancer-related lipid metabolism.
We sought to investigate the role of LPAATb in regulating OS
cell proliferation and tumor growth. LPAATb expression is readily
detected in most OS cell lines. Exogenous expression of LPAATb
promotes OS cell proliferation and migration, while silencing
LPAATb expression inhibits cell proliferation and migration.
Using an orthotopic xenograft model of human OS, we have
demonstrated that exogenous expression of LPAATb effectively
promotes OS tumor growth, while knockdown of LPAATb
reduces OS tumor volume in the xenograft model. Taken
together, our results strongly suggest that LPAATb expression
may be associated with aggressive phenotypes of human OS and
that LPAATb may play an important role in regulating OS cell
proliferation and tumor growth. Therefore, targeting LPAATb
may be exploited as a novel therapeutic strategy for the clinical
management of OS.
Materials and Methods
Tumor lines, cell culture and chemicals
No human subjects were used in the reported studies. However,
tumor cell lines derived from patients were used, which has been
approved by the Institutional Review Board (protocol #17043B).
HEK293 and human OS lines 143B, SaOS2, MG63 and TE85
were purchased from ATCC (Manassas, VA). MG63.2 cell line
was established by serially passaging the parental MG63 cells in
mice followed by extraction and culture of pulmonary metastasis
as previously described [38,39]. Primary OS cells were isolated
from resected OS specimens as previously described [15,40,41].
Cells were maintained in complete Dulbecco’s Modified Eagle’s
Medium (DMEM) containing 10% FCS (fetal calf serum,
HyClone, Logan, UT) at 37uC in 5% CO2. Unless otherwise
indicated, all chemicals were purchased from Sigma-Aldrich (St
Louis, MO) or Fisher Scientific (Pittsburgh, PA).
Generation of recombinant adenoviruses expressing RFP,
LPAATb and siLPAATb
Recombinant adenoviruses were generated using AdEasy
technology as previously described [42–46]. Briefly, the coding
region of mouse LPAATb was PCR amplified and cloned into the
adenoviral shuttle vector pAdTrace-TO4 and subsequently used
to generate recombinant adenovirus in HEK293 cells. Similarly,
four short interfering RNA (siRNA)-coding oligonucleotides
against human LPAATb were designed by using Dharmacon’s
siDESIGN program. The oligonucleotide cassettes were cloned into
pSES shuttle vector as previously described [47–49]. All constructs
were verified by DNA sequencing. Recombinant adenoviruses,
designated as AdR-LPAATb and AdR-siLPAATb, were generat-
ed as previously described [42–46]. AdR-LPAATb and AdR-
siLPAATb express RFP as a marker for monitoring infection
efficiency. Analogous adenovirus expressing monomeric RFP (Ad-
RFP) was used as control [44,50,51].
RNA isolation and semi-quantitative RT-PCR analysis
Total RNA was isolated using TRIZOL Reagents (Invitrogen)
and cDNA was generated via reverse transcription reaction with
hexamer and Superscript II RT (Invitrogen). The first strand
cDNA products were further diluted 5- to 10-fold and used as
PCR templates. Semi-quantitative RT-PCR was carried out using
PCR primers designed by using the Primer3 program to amplify
the gene of interest (approximately 150–180 bps). Primers used
were as follows: human LPAATb,5 9- CCT TCC TCC ACA
TCT CCA AG-39 and 59- CCG GAC AGA GTG GTA TTT
GG-39; human GAPDH, 59- CAA CGA ATT TGG CTA CAG
CA-39 and 59- AGG GGA GAT TCA GTG TGG TG-39; and
mouse LPAATb,5 9-GCG GAC AGA AGA AAC TGG AG-39
and 59-TGA AGT AGA CAC CCC CAA GG-39. Touchdown
PCR reactions were carried out as previously described
[15,41,48,49,52–54]. PCR products were separated via 1.2%
agarose gels. The resulting bands were analyzed in Kodak
ImageStation 440CF using Kodak 1D 3.6 software.
Crystal violet staining
Subconfluent cells were seeded in 12-well plates and infected
with an optimal titer of AdR-LPAATb, AdR-siLPAATb or
AdRFP. Cells were subjected to crystal violet staining at 5 days
after infection as previously described [41,55]. Images were taken
from the plates relative staining intensities were analyzed by using
ImageJ software.
Cell proliferation (MTT) assay
MTT assay was used to quantitatively analyze cell proliferation
as previously described [15,41,56]. Briefly, cells were seeded in 96-
well plates and infected with AdR-LPAATb, AdR-siLPAATb or
AdRFP. Cell proliferation was assessed by MTT assay daily for
five days. Optical absorbance was measured at 570 nm using a 96-
well microplate reader. All experiments were performed in
triplicate.
Cell migration and wound healing assay
The experiments were carried out essentially as described
previously [15,16,39,41,53,57]. Subconfluent cells were plated into
6-well plates and infected with AdR-LPAATb, AdR-siLPAATb or
AdRFP in 1% FCS containing medium. At 16 h after infection,
the monolayer of cells was wounded using micropipet tips. Marks
were created on the plates using 18-gauge needles as reference
points for serial imaging. Bright field images of the same field were
taken at 4, 12, 24, and 36 hours. The results were repeated in at
least two batches of experiments.
Orthotopic tumor model of human osteosarcoma
The reported animal work was carried out according to the
guidelines approved by the Institutional animal Care and Use
Committee (Protocol #71328). Athymic nude (nu/nu) mice (4–6
week-old, male) were used (5 mice per group, Harlan Laborato-
ries, Indianapolis, IN). Human OS cells (e.g., 143B or MG63)
were stably transduced with a retroviral vector expressing firefly
luciferase (namely 143B-Luc or MG63-Luc). Cells were seeded in
LPAAT b in Human Osteosarcoma
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AdR-siLPAATb or AdRFP. At 36–48 h after infection cells were
collected and resuspended in PBS to a final concentration of
2610
7 cells/ml. 50 ul of the resuspened cells (i.e., 10
6 cells/
injection) were periosteally injected posterior to the proximal tibia
using a 25 gauge needle.
Xenogen bioluminescence imaging
Xenogen imaging was carried out as described [15,41]. Animals
were anesthetized with isoflurane. Approximately 10 min prior to
using Xenogen IVIS 200 imaging system, animals were injected
(ip) with D-Luciferin sodium salt (Gold BioTechnology) at
100 mg/kg in 0.1 ml sterile PBS. The pseudoimages were
obtained by superimposing the emitted light over the gray-scale
photographs of the animal. Quantitative analysis was done with
Xenogen’s Living Image V2.50.1 software.
Tumor volume measurement
The dimensions of the primary tumor sites were measured every
3–4 days. The volume was calculated as previously reported [38,39],
by using the following equation: volume = (L+W)(L)(W)(0.2618).
The width (W) was an average of the distance at the proximal tibia at
the level of the knee joint in the anterior-posterior and medial-lateral
planes. The length (L) was the distance from the most distal extent of
the calf musculature or distal tumor margin to the knee joint or
proximal tumor margin [39].
Histological analysis
Animals were sacrificed and the primary tumors were harvested
at necropsy and fixed in 10% formalin or decalcification solution
(Cal-Ex, Fisher Scientific). The fixed samples were embedded in
paraffin. Sections were stained with hematoxylin and eosin, and
analyzed under a microscope.
Immunohistochemical staining
Immunohistochemical analysis was carried out as previously
described previously [14–16,39,41]. Briefly, paraffin sections were
deparaffinized, rehydrated and probed with anti-LPAATb, anti-
PCNA, or isotype IgG, followed by incubation with secondary
antibodies conjugated with HRP. The expression of expected
proteins was visualized by DAB staining and examined under a
microscope. Stains without the primary antibody, or with control
IgG, were used as negative controls.
Statistical analysis
Microsoft Excel was used to calculate standard deviations (SD)
and statistically significant differences between samples using the
two-tailed Student’s t-test. For all quantitative assays, each assay
condition was performed in triplicate and the results were repeated
in at least three independent experiments. All collected data were
subjected to statistical analysis. A p-value ,0.05 was defined as
statistically significance.
Results
LPAATb is expressed in most human OS cells
In order to understand the possible role of LPAATb in human
OS tumorigenesis and progression, we analyzed the endogenous
expression of LPAATb in a panel of human OS cell lines. We first
assessed the expression of LPAATb in the four commercially
available OS lines (i.e., MG63, 143B, TE85, and SaOS2) and the
line MG63.2 derived from MG63 [38]. As shown in Fig. 1A,
expression of LPAATb was readily detected in three of the five
lines. Interestingly, expression of LPAATb is more apparent in
lines with higher xenogenic tumor growth potential, such as 143B,
MG 63, and MG63.2 as compared to lines with less tumorigenic
capacity, such as TE85 and SaOS2 [39]. We next examined the
expression of LPAATb in five OS lines derived from OS patients
[15,40,41]. Three of the five patient-derived OS lines exhibited
apparent expression of LPAATb while other two lines showed
weak but detectable expression of LPAATb (Fig. 1B). Our
previous studies indicated that UCHOS4 and UCHOS15 lines
were more tumorigenic than UCHOS11 cells [15,40,41]. The
expression of LPAATb at protein level was further confirmed in
xenograft tumors formed by 143B and MG63.2 cells (Fig. 1C).
Taken together, these results indicate that LPAATb is commonly
expressed in human OS cells and that LPAATb expression is
seemingly correlated with aggressive phenotype of OS cell lines’.
LPAATb promotes cell viability and proliferative activity
of OS cells
In order to further investigate the functional role of LPAATb in
OS proliferation and tumor growth, we sought to generate
recombinant adenoviruses that can effectively over-express
LPAATb (AdR-LPAATb) and siRNAs targeting human LPAATb
(AdR-siLPAATb) using the AdEasy technology [44,45]. We
constructed an adenoviral vector that over-expresses mouse
LPAATb driven by a CMV promoter (Fig. 2A). The siRNA
expressing adenoviral vectors were constructed using the pSOS
system [46,47,49], for which four target sites were chosen
(Fig. 2B). The generated adenoviruses, which also express the
RFP maker, were shown to effectively transduce 143B cells
(Fig. 2C) and other OS lines (data not shown). We further
demonstrated that AdR-LPAATb effectively overexpressed mouse
LPAATb mRNA while human LPAATb mRNA was significantly
knocked down by AdR-siLPAATb (Fig. 2D), indicating that the
adenoviral vectors are functional.
Using these adenoviral vectors, we investigated the effect of
overexpression or knockdown of LPAATb on OS cell viability and
proliferation. Using the crystal violet viability assay, we found that
over-expression of LPAATb promoted 143B proliferation and
increased viable cells, whereas knockdown of LPAATb led to a
decrease in cell proliferation and viability of 143B cells (Fig. 3A).
Quantitative analysis of the crystal violet staining results indicated
that the increase in cell viability and proliferation resulted from
LPAATb overexpression or the decrease in cell viability and
proliferation caused by LPAATb knockdown was statistically
significant when compared with the control cells (Fig. 3B). The
effect of LPAATb on OS cell proliferation was further assessed by
MTT assay. Consistent with the results obtained from crystal
violet staining assay, overexpression of LPAATb promoted OS cell
proliferation while silencing LPAATb expression inhibited cell
proliferation (Fig. 3C). These results were reproducible in other
OS cell lines (data not shown). Taken the above findings together,
LPAATb expression can enhance OS cell viability and prolifer-
ation in vitro.
LPAATb enhances OS cell migration in vitro
The ability of tumor cells to migrate is considered an important
indicator of tumor cell’s aggressiveness. To assess the effect of
LPAATb on OS cell migration in vitro, we conducted the
commonly-used cell wounding experiment [15,16,39,41,53,57].
We found that over-expression of LPAATb effectively promoted a
faster wound healing than that of the control cells (Fig. 4A vs. 4B).
Conversely, knockdown of LPAATb expression inhibited cell
migration and wound healing, at least in the duration of the testing
period (Fig. 4C vs. 4B). Similar results were obtained from
LPAAT b in Human Osteosarcoma
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above results strongly suggest that LPAATb expression may be
related to OS cell migration-related aggressiveness phenotype.
Overexpression of LPAATb promotes tumor growth in an
orthotopic model of human OS tumors
We further analyzed the effect of LPAATb expression on OS
tumor growth in vivo. Using our previously established orthotopic
tumor model of human OS [15,38,39,41], we found that 143B cells
transduced with LPAATb formed much larger tumors than that of
the control group’s, whereas knockdown LPAATb led to the
inhibition of tumor growth (Fig. 5A). Quantitative analysis of the
Xenogen bioluminescence imaging data revealed that overexpres-
sion of LPAATb significantly promoted OS tumor growth,
especially at the late stage (p,0.05) while knockdown of LPAATb
did not significantly affect Xenogen imaging signal (Fig. 5B).
Figure 1. Endogenous expression of LPAATb in human osteosarcoma cell lines. A. Semi-quantitative RT-PCR analysis of LPAATb expression
in the five commonly used OS lines MG63, MG63.2, 143B, TE85, and SaOS2. GAPDH expression was used as an internal control. B. Semi-quantitative
RT-PCR analysis of LPAATb expression in the five primary OS cell lines derived from OS tumors. GAPDH expression was used as an internal control. C.
Immunohistochemical staining of LPAATb expression in xenograft tumors formed by MG63.2 and 143B cells in athymic nude mice. Expression of
LPAATb was detected by using a LPAATb antibody. Isotype IgG was used as a control for immunohistochemical staining.
doi:10.1371/journal.pone.0014182.g001
LPAAT b in Human Osteosarcoma
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quantitative, the imaging results may not be reliable when tumors
have necrosis and/or are less vascularized. Thus, we also
measured the tumor sizes during the course of the study, and
found that the overall tumor growth trends were in general
consistent with that of Xenogen imaging analysis (Fig. 5C).
However, the tumor volume was reduced in the LPAATb
knockdown group (p,0.05). The calculated doubling time was
9.30 days for RFP control group, 11.99 days for the siLPAATb
group, and 6.64 days for the LPAATb group, indicating that
tumors with LPAATb over-expression had a significantly shorter
doubling time than that of the control group (p,0.02).
Figure 2. Construction and characterization of recombinant adenovirus that expresses mouse LPAATb or knocks down human
LPAATb.A . Schematic representation of adenoviral shuttle vector that overexpresses LPAATb driven by CMV promoter (for making AdR-LPAATb).
The shuttle vector also expresses RFP marker. B. Schematic representation of adenoviral pSOS shuttle vector that expresses siRNA driven by dual
opposing promoters (for making AdR-siLPAATb). The pSOS shuttle vector also expresses RFP marker. The four siRNA targeting sites against human
LPAATb are listed. C. Adenovirus-mediated effective transduction of human osteosarcoma cells. Optimal titer of the recombinant adenoviruses AdR-
LPAATb and AdR-siLPAATb were used to infect 143B cells. The expression of red fluorescent protein (RFP) was examined at 48 h after infection. D.
Characterization of AdR-LPAATb-mediated overxpression and AdR-siLPAATb-mediated knockdown. Subconfluent 143B cells were infected with AdR-
LPAATb, AdR-siLPAATb, or AdRFP control for 48 h. Total RNA were collected and subjected to RT-PCR. The resultant cDNA was subjected to semi-
quantitative PCR using primers specific for mouse LPAATb mRNA (for AdR-LPAATb infection) or human LPAATb mRNA (for AdR-LPAATb infection).
GAPDH was used as an internal control to normalize all samples.
doi:10.1371/journal.pone.0014182.g002
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well plates and infected with an optimal titer of AdR-LPAATb, AdR-LPAATb, or AdRFP control. Viable cells were subjected to crystal violet staining at 5
days after infection. Representative duplicate staining is shown. B. Quantitative analysis of the crystal violent staining assay. Relative staining
intensities were measured by using ImageJ software. ‘‘*’’ p-value ,0.05. C. MTT cell proliferation. 143B cells were seeded in 96-well plates and
infected with an optimal titer of AdR-LPAATb, AdR-LPAATb, or AdRFP control (in triplicate). At the indicated time points after infection, cells were
subjected to MTT assay to determine relative proliferative activity. ‘‘*’’ p-value ,0.01.
doi:10.1371/journal.pone.0014182.g003
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tumor samples. H & E staining revealed that the LPAATb
overexpression group exhibited increased cell numbers with
relatively higher nuclear to cytoplasmic ratio (1.7), while the
LPAATb knockdown group has demonstrates relatively lower
nuclear to cytoplasmic ratio (0.73) When compared to RFP group
(1.2) (Fig. 6 top panel). Proliferative activity of the tumor cells was
assessed by anti-PCNA immunohistochemical staining. Consistent
with H & E staining, the LPAATb overexpression group exhibited
increased cell proliferation whereas the LPAATb knockdown
group showed relatively low proliferative activity (Fig. 6 bottom
panel). Taken together, these in vivo results strongly suggest that
LPAATb may play an important role in promoting OS tumor
growth.
Discussion
OS is the most common primary malignancy of bone [1–4,58].
Although clinical management of OS has significantly improved,
survival rate in the last few decades has plateaued. This bottle-neck
has been a consequence of our poor understanding of the
molecular mechanism underlying OS development and progres-
sion. Here, we investigate the role of LPAATb in OS cell
proliferation and tumor growth. LPAATb expression is readily
detected in most OS cell lines. Exogenous expression of LPAATb
promotes OS cell proliferation and migration, while silencing
LPAATb expression inhibits cell proliferation and migration.
Using an orthotopic xenograft model of human OS, we
demonstrate that exogenous expression of LPAATb effectively
promotes OS tumor growth, while knockdown of LPAATb
reduces OS tumor volume in the xenograft model. These results
suggest that LPAATb may play an important role in regulating
OS cell proliferation and tumor growth.
Our in vitro results suggest that the expression level of LPAATb
may correlate with OS malignant characteristics. We have found
an increased level of LPAATb in tumors with highly malignant
OS lines, such as MG63.2, 143B and UCHOS4, whereas
LPAATb expression level is lower in OS lines that are more
differentiated and with lower malignant characteristics, such as
TE85 and SaOS [15,39]. However, further studies on LPAATb
expression level needs to be carried out on a large set of clinical
OS samples in order to determine if LPAATb expression may
serve as an indicator of OS aggressive phenotypes.
LPAATs are a family of enzyme that catalyses the biosynthesis
of PA [22]. Overexpression of LPAATb has been shown to
transform cells in vitro [59]. LPAATb is highly expressed in
advanced ovarian tumors and is associated with aggressive
histology and decreased overall survival [60–63]. Chemical
inhibitors of LPAATb exhibit anti-tumor activity and promote
apoptosis in lymphomas, acute leukemia, and multiple myeloma
[59,64–67]. Inhibition by either genetic means or by isoform-
specific small molecules results in a block to cell signaling pathways
and apoptosis [59].
PA is a versatile lipid second-messenger that functions as a
cofactor in several critical signaling pathways in cancer cells. For
example, the full activation of c-Raf-1 and B-raf is manifested only
when phosphatidic acid physically interacts with a polybasic amino
acid segment in these kinases [28]. This interaction is required for
the translocation of Raf kinases to the plasma membrane where
they phosphorylate and activate their targets. Moreover, binding
of phosphatidic acid to a polybasic domain in mTOR is essential
for its activation [30]. Thus, the role of phosphatidic acid is central
to the regulation of proteins in both proliferative and survival
pathways in tumor cells. We found that silencing LPAATb
expression in osteosarcoma cells resulted in decreased expression
of c-Myc, cyclin D1, c-Fos, and MDM2, but an increased Rb
expression (data not shown). Nonetheless, the exact role of
LPAATb in OS development remains to be investigated.
It has been reported that inhibition of LPAATb with small
interfering RNA or selective inhibitors CT32521 and CT32228
induces apoptosis in human ovarian and endometrial cancer cell
Figure 4. Effect of LPAATb on osteosarcoma cell migration (wound healing assay). Subconfluent 143B cells were seeded in 6-well plates
and infected with AdR-LPAATb (A), AdRFP (B), or AdR-siLPAATb (C) for 24 h in growth media containing 1% FCS. A scratch wound was introduced
across the subconfluent monolayer of cells in each well. Bright field images of the same fields were recorded at the indicated time points. The assays
were repeated in at least two independent batches of experiments. Representative results are shown.
doi:10.1371/journal.pone.0014182.g004
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PLoS ONE | www.plosone.org 7 December 2010 | Volume 5 | Issue 12 | e14182Figure 5. Effect of LPAATb on tumor growth in the orthotopic model of osteosarcoma. A. Xenogen IVIS 200 bioluminescence imaging of
orthotopic tumor growth. Athymic nude mice were periosteally injected at proximal tibia with 143B cells infected with AdR-LPAATb, AdRFP, or AdR-
siLPAATb for 15 h (10
6 cells/injection). Animals were subjected to Xenogen imaging at the indicated time points. Representative imaging results at 37
days post injection are shown. B. Quantitative analysis of Xenogen imaging signal intensity (photons/sec/cm
2/steradian) over the time after injection.
C. Tumor growth as determined by tumor volume. The dimensions of injection sites were measured roughly every 3 days during the course of study.
Tumor volumes (mm
3) were calculated as described in Methods. ‘‘*’’ p-value ,0.05, ‘‘**’’ p-value ,0.001.
doi:10.1371/journal.pone.0014182.g005
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tumor xenografts [61]. Previous studies have also demonstrated
that inhibition of LPAATb expression with siRNA in mammalian
cells suppresses basal Erk phosphorylation [68]. Inhibition of
LPAATb with small-molecule antagonists prevents the transloca-
tion of Raf to the plasma membrane and subsequent Erk
phosphorylation [68]. These inhibitors also suppress the activation
of proteins in the phosphoinositide-3-kinase/Akt pathway, includ-
ing Akt, mTOR, and S6 kinase [68]. Therefore, it is conceivable
that LPAATb may be exploited as a novel cancer drug target for
OS clinical management.
Taking together, we have conducted in vitro and in vivo studies to
investigate the role of LPAATb in OS cell proliferation and tumor
growth. Our results indicate that exogenous expression of
LPAATb promotes OS cell proliferation and migration, while
silencing LPAATb expression inhibits cell proliferation and
migration. Furthermore, exogenous expression of LPAATb
effectively promotes OS tumor growth, while knockdown of
LPAATb reduces OS tumor volume in an orthotopic xenograft
model of human OS. These results strongly suggest that LPAATb
expression may be associated with aggressive phenotypes of
human OS and that LPAATb may play an important role in
regulating OS cell proliferation and tumor growth. Therefore,
targeting LPAATb may be exploited as a novel therapeutic
strategy for OS clinical management. This is especially attractive
given the availability of selective pharmacological inhibitors.
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